Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 834

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 3
Chunk 834
---
 director of LogicMark, Inc. (Nasdaq: LGMK), a company that develops medical alert devices
and related technologies. Ms. Simmons served as a member of the governing board of directors for Servco Pacific Inc., a global
automotive and consumer goods company with businesses in mobility, automotive distribution and sales, and entertainment and currently
serves on its Investment Board. Ms. Simmons serves on the board of New Energy Nexus, an international organization that supports
clean energy entrepreneurs with funds, accelerators, and networks. From 2016 to June 2021, Ms. Simmons served as the Chief Executive
Officer and co-founder of LookyLoo, Inc., an artificial intelligence social commerce company. From 2014 to 2016, Ms. Simmons served
as Head of Global Partner Marketing at Google Play, prior to which, between 2010 and 2014, she served as VP of Marketing &
Content for Harman International. Ms. Simmons received her B.A. in Communications, Magna cum Laude, and Phi Beta Kappa, from the
University of California, San Diego in 1995. She also received her M.B.A. from Cornell University in 2002, where she was a Park
Leadership Fellow, and her J.D. from George Mason University in 2005, and is currently a licensed attorney in the State of New
York. She was selected to serve on our board of directors due to her experience serving on the boards of directors of public companies. 

Family
Relationships

There
are no family relationships among any of our directors or executive officers.

Involvement
in Certain Legal Proceedings 

None.

Code
of Ethics 

We
have a written code of conduct and ethics that applies to our directors, officers, employees and contractors, including our principal
executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions.
The code of conduct and ethics is available on our website at www.channeltherapeutics.com. We intend to disclose
future amendments to such code, or any waivers of its requirements, applicable to any principal executive officer, principal financial
officer, principal accounting officer or controller, or persons performing similar functions or our directors on our website identified
above or in a Current Report on Form 8-K that we would file with the SEC.

Delinquent
Section 16(a) Reports 

Under
the securities laws of the United States, our directors, executive (and certain other